 November 15, 2017 - By Vivian Park Among 3 analysts covering Turkcell (NYSE:TKC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Turkcell had 4 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) earned “Neutral” rating by Bank of America on Thursday, September 3. The rating was upgraded by Deutsche Bank on Thursday, January 5 to “Buy”. JP Morgan downgraded the shares of TKC in report on Wednesday, April 6 to “Neutral” rating. On Thursday, September 17 the stock rating was upgraded by JP Morgan to “Overweight”. See Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) latest ratings:The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today! About 665,314 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since November 15, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.The move comes after 6 months positive chart setup for the $82.81 billion company. It was reported on Nov, 15 by Barchart.com. We have $35.45 PT which if reached, will make NYSE:AZN worth $4.97 billion more.Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 1. They expect $0.47 earnings per share, down 61.16% or $0.74 from last year’s $1.21 per share. AZN’s profit will be $1.16B for 17.79 P/E if the $0.47 EPS becomes a reality. After $1.12 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -58.04% negative EPS growth.Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by Deutsche Bank given on Monday, September 14. As per Wednesday, April 5, the company rating was downgraded by UBS. The firm has “Hold” rating by Liberum Capital given on Thursday, September 14. The stock has “Buy” rating by Liberum Capital on Friday, November 25. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Buy” rating given on Monday, October 16 by Credit Suisse. On Friday, December 9 the stock rating was upgraded by Leerink Swann to “Outperform”. The stock has “Underperform” rating by Credit Suisse on Tuesday, October 20. Swedbank upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Friday, July 31 to “Buy” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, July 28. As per Monday, February 8, the company rating was downgraded by HBSC.AstraZeneca PLC is a biopharmaceutical company. The company has market cap of $82.81 billion. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 23.91 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. About 106,620 shares traded. Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) has declined 9.06% since November 15, 2016 and is downtrending. It has underperformed by 25.76% the S&P500.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.